Radiation Oncology

Radiation oncology is a medical specialty that uses radiation therapy to treat cancer. The radiation therapy channel covers all aspects of radiation oncology technology. Radiation therapy includes linear accelerators (LINAC), proton therapy, brachytherapy, image guided radiation therapy (IGRT), focused ultrasound, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), treatment planning systems and tomotherapy.

Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
Varian Brings Machine Learning to Proton Treatment Planning
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced...
read more
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
Artificial Intelligence Greatly Speeds Radiation Therapy Treatment Planning
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new...
read more
Collaboration offers clinicians a personalized oncology solution that combines cutting-edge MRI-guided radiation therapy with a leading AI-driven EMR integration platform
News | Radiation Oncology | April 01, 2020
ViewRay and VieCure Announce Strategic Collaboration to Accelerate Adoption of Personalized Cancer Care
April 1, 2020 — ViewRay, Inc. announced a strategic collaboration with VieCure, an artificial intelligence (AI)...
read more
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
A New Paper on the Pros and Cons of Radiotherapy
March 30, 2020 — Women undergoing radiotherapy for many cancers are more likely than men to be cured, but the side...
read more
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
Managing Prostate Cancer Patients During the COVID-19 Pandemic
March 30, 2020 — In the wake of the COVID-19 pandemic, a team of radiation oncologists from the U.S. and U.K. is...
read more
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
High-resolution PET/CT Assesses Brain Stem Function in Patients with Hearing Impairment
March 26, 2020 — Novel, fully digital, high-resolution positron emission tomography/computed tomography (PET/CT)...
read more
PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning
News | Prostate Cancer | March 23, 2020
Prostate Cancer Study Finds Molecular Imaging Could Transform Management of Patients with Aggressive Cancer
March 23, 2020 — Results from a randomised controlled trial involving 300 prostate cancer patients find that a...
read more
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
CDC Reports Cancer Death Rates Continue to Decline
March 16, 2020 — The Annual Report to the Nation on the Status of Cancer finds that cancer death rates continued to...
read more
Reflexion eceived marketing clearance from the U.S. Food & Drug Administration (FDA) for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT) for its RefleXion X1 machine
News | Stereotactic Body Radiation Therapy (SBRT) | March 13, 2020
FDA Clearance Brings RefleXion Closer to Expanding Cancer Treatment Market
March 13, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (...
read more
The guidance gives clarity and evidence to explain why the use of patient contact shielding to protect critical organs is no longer necessary for patients
News | Radiation Dose Management | March 13, 2020
BIR Offers Guidance on Why Patient Contact Shielding is no Longer Needed
March 13, 2020 — The British Institute of Radiology (BIR) and a working party of U.K. radiological professional bodies...
read more
M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers. (c) University of Maryland Greenebaum Comprehensive Cancer Center

News | Prostate Cancer | March 05, 2020
Adding MRI-targeted Biopsy Leads to More Reliable Diagnosis of Aggressive Prostate Cancer
March 5, 2020 — Using a combination of magnetic resonance imaging (MRI) to target and sample suspicious prostate tissue...
read more
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
First Accuray CyberKnife M6 System Installed in Missouri
February 27, 2020 — Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its...
read more
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
Finding New Clues to Brain Cancer Treatment
February 21, 2020 — Glioblastoma is an aggressive, killer disease. While victims of this fast-moving brain tumor...
read more
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
A New Way to Monitor Cancer Radiation Therapy Doses
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical. Too much...
read more
The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from the U.S. Department of Veterans Affairs (VA) to develop quality indicators (QI) for radiation treatments provided to veterans with head and neck, breast and gastrointestinal cancers
News | Radiation Therapy | February 13, 2020
ASTRO Awarded Contract from VA to Develop Measures on Quality of Radiation Therapy Services
February 13, 2020 — The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from...
read more
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
Varian Receives FDA 510(k) Clearance for Ethos Therapy
February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive...
read more
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
Global Radiation Therapy Market to Reach $8.6B by 2026
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
read more
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
Interventional Radiologists can be “Game Changers” in the Treatment of Kidney Cancer
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
read more
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
Studies Support Use of Accuray TomoTherapy System for Advanced Rectal Cancer
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the TomoTherapy ...
read more
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
Purdue-discovered ‘Fluorescent Markers’ Illuminate Cancer, Improve Outcomes
February 6, 2020 — On Target Laboratories Inc., a privately held biotechnology company developing the use of Purdue...
read more
© Copyright Wainscot Media. All Rights Reserved.